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Abstract
Background: In some autistic children, there is an imbalance of T helper (Th)1/Th2 lymphocytes toward Th2, which
may be responsible for the induction of the production of autoantibodies in these children. Th2 lymphocytes
express CCR4 receptors. CCR4 ligands include macrophage-derived chemokine (MDC) and thymus and
activation-regulated chemokine (TARC). They direct trafficking and recruitment of Th2 cells. We are the first to
measure serum levels of CCR4 ligands in relation to the degree of the severity of autism.
Methods: Serum concentrations of MDC and TARC were measured, by quantitative sandwich enzyme
immunoassay technique, in 56 autistic children and 32 healthy matched children.
Results: Autistic children had significantly higher serum levels of MDC and TARC than healthy controls
(P <0.001 and P <0.001, respectively). Children with severe autism had significantly higher serum levels of MDC and
TARC than patients with mild to moderate autism (P <0.001 and P = 0.01, respectively). In addition, there were
significant positive correlations between CARS and serum levels of both MDC (P <0.001) and TARC (P <0.001) in
children with autism. There were significant positive correlations between serum levels of MDC and TARC in autistic
children (P <0.001).
Conclusions: Serum levels of CCR4 ligands were elevated in autistic children and they were significantly correlated
to the degree of the severity of autism. However, further research is warranted to determine the pathogenic role of
CCR4 ligands in autism and to shed light on the therapeutic role of CCR4-ligand antagonism in autistic children.
Keywords: Autism, Autoimmunity, Childhood Autism Rating Scale, CCR4 ligands, Macrophage-derived chemokine,
Thymus and activation-regulated chemokine
Background
Recruitment of inflammatory cells plays the key patho-
genic role in all inflammatory and autoimmune diseases.
Inflammation is characterized by the local tissue expres-
sion of chemokines, a large group of chemotactic
cytokines, which play an important pathogenic role in
inflammatory diseases by enhancement of leukocyte
recruitment and activation at inflammatory sites [1-4].
CCR4 is a receptor that binds two 8 kDa CC
chemokines, macrophage-derived chemokine (MDC/
CCL22) and thymus and activation-regulated chemokine
(TARC/CCL17) [5]. MDC is synthesized by cells of
macrophage lineage, while TARC is expressed in the
thymus. The gene encoding both chemokines is clustered
on chromosome 16q13 [6-8]. CCR4 ligands, MDC and
TARC, act on their CCR4 receptors to enhance the re-
cruitment and activation of T helper (Th) 2 cells with a
subsequent production of type 2 cytokines that include
interleukin-4 (IL-4), IL-5, IL-9 and IL-13 [9,10]. The Th2-
associated chemokines, MDC and TARC, were the highest
at birth and then decreased with age [11]. CCR4 ligands
have an important pathogenic role in inflammatory condi-
tions such as allergy and some autoimmune diseases
[12-18]. Chemokines and their receptors have been
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implicated as functional mediators of immunopathology
of autoimmune neuroinflammatory diseases [19,20].
The presence of autoantibodies to neural tissues/anti-
gens in autism [21-28] and the increase in the frequency
of autoimmune disorders among autistic families [29-33]
suggest that autoimmunity may play an important role
in the pathogenesis of autism [21].
This study aimed to measure serum levels of CCR4
ligands in relation to the degree of the severity of autism
in a group of autistic children.
Methods
Study population
This cross-sectional study was conducted on 56 autistic
children. They were recruited from the Autism Research
and Treatment Center, Faculty of Medicine, King Saud
University, Riyadh, Saudi Arabia. Patients fulfilled the
criteria of the diagnosis of autism according to the 4th
edition of the Diagnostic and Statistical Manual of
Mental Disorders [34]. The autistic group comprised 46
males and 10 females. Their ages ranged between 4 and
12 years (mean ± SD = 7.54 ± 1.96 years). Patients who
had associated neurological diseases (such as cerebral
palsy and tuberous sclerosis), metabolic disorders (for
example phenylketonuria), allergic manifestations or
concomitant infection were excluded from the study.
The control group comprised 32 age- and sex-
matched apparently healthy children. They included 26
males and 6 females. They were the healthy older sib-
lings of the healthy infants who attend the Well Baby
Clinic, King Khalid University Hospital, Faculty of Medi-
cine, King Saud University, Riyadh, Saudi Arabia for the
routine following up of their growth parameters. The
control children were not related to the children with
autism, and demonstrated no clinical findings suggestive
of infections, allergic manifestations and immunological
or neuropsychiatric disorders. Their ages ranged be-
tween 5 and 11 years (mean ± SD = 7.19 ± 1.69 years).
The local Ethical Committee of the Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia, approved
this study. In addition, an informed written consent of
participation in the study was signed by the parents or
the legal guardians of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, the degree of the disease severity was
assessed by using the Childhood Autism Rating Scale
(CARS) [35] which rates the child on a scale from one
to four in each of fifteen areas (relating to people; emo-
tional response; imitation; body use; object use; listening
response; fear or nervousness; verbal communication;
nonverbal communication; activity level; level and
consistency of intellectual response; adaptation to
change; visual response; taste, smell and touch response
and general impressions). According to the scale,
children who have scored 30 to 36 have mild to mode-
rate autism (n = 20), while those with scores ranging bet-
ween 37 and 60 points have a severe degree of autism
(n = 36).
Serum assessment of MDC and TARC levels
The assay employed the quantitative sandwich enzyme
immunoassay technique using the Quantikin Human
MDC/CCL22 and TARC-CCL17 immunoassay kits (both
kits were supplied from R&D Systems Inc., Minneapolis,
MN, USA). A monoclonal antibody specific for MDC or
TARC had been precoated onto a microplate. Standards
and samples were pipetted into the wells and any MDC or
TARC present was bound by the immobilized antibody.
After washing away any unbound antibody-enzyme re-
agent, a substrate solution was added to the wells and
color developed in proportion to the amount of MDC or
TARC bound in the initial step. The color development
was stopped and the intensity of the color was measured
[7,16]. To increase accuracy, all samples were analyzed
twice in two independent experiments to assess the
interassay variations and to ensure reproducibility of the
observed results. There were no discordant data between
the results (P >0.05). No significant cross-reactivity or
interference was observed.
Statistical analysis
The results were analyzed by using the commercially
available software package (Statview, Abacus Concepts,
Inc., Berkley, CA, USA). The data were nonparametric,
thus they were presented as median and interquartile
range (IQR), which are between the 25th and 75th per-
centiles. The Mann–Whitney test was used for compari-
son between these data. A chi-square test was used for
comparison between qualitative variables of the studied
groups. Spearman’s rho correlation coefficient ‘r’ was
used to determine the relationship between different
variables. For all tests, a probability (P) of less than 0.05
was considered significant.
Results
Autistic children had significantly higher serum levels of
MDC (median (IQR) = 1289.5 (1079) pg/ml) than healthy
controls (median (IQR) = 190 (295) pg/ml), P <0.001
(Figure 1). Similarly, autistic children had significantly
higher serum levels of TARC (median (IQR) = 880.5
(1206) pg/ml) than healthy children (median (IQR) =
137.25 (173) pg/ml), P <0.001, (Figure 2).
Children with severe autism had significantly higher
serum levels of MDC and TARC than patients with mild
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to moderate autism (P < 0.001 and P = 0.01, respectively),
Table 1. In addition, there were significant positive cor-
relations between CARS and serum levels of both MDC
(r = 0.93, P < 0.001) and TARC (r = 0.87, P < 0.001) in
children with autism.
There were significant positive correlations between
serum levels of MDC and TARC in autistic children,
P < 0.001 (Figure 3).
Serum levels of both MDC and TARC had no signifi-
cant correlations with the age of the children with
autism (P = 0.87 and P = 0.47), respectively. In addition,
there was no significant difference between male and
female autistic children in serum levels of both MDC
(P >0.05) and TARC (P >0.05).
All study subjects had normal weight (body mass
index (BMI) was between the 5th and less than the 85th
percentiles based on age and sex). There was no signifi-
cant difference between the BMI of healthy children and
autistic children (P >0.05). In addition, there were no
significant correlations between the BMI and serum
levels of both MDC (P >0.05) and TARC (P >0.05) in
children with autism.
Discussion
CCR4 ligands direct trafficking and recruitment of Th2
cells [9,10] and they were reported to play an important
role in some autoimmune diseases [15-18]. In the
present study, autistic children had significantly higher
serum levels of MDC and TARC than healthy controls
(P <0.001 and P <0.001, respectively). A previous study
reported increased MDC and TARC in the anterior cin-
gulate gyrus of autistic patients [36]. Proinflammatory
chemokines, such as TARC and monocyte chemotactic
protein-1 (MCP-1) along with proinflammatory cyto-
kines were reported to be elevated in the brains of some
individuals with autism.
The transport or synthesis of cytokines in the brain may
contribute to neuroinflammation and possible neurotrans-
mitter imbalances in autism [21]. Abnormal immune re-
sponses, as assessed by multiplex analysis of cytokines and
chemokines, may serve as one of the biological trait
markers for autism [37]. Active neuroinflammatory
process in the cerebral cortex, white matter, and notably
in cerebellum of autistic patients was reported. Immuno-
cytochemical studies showed marked activation of micro-
glia and astroglia, and cytokine profiling indicated that
macrophage chemoattractant protein-1 and tumor growth
factor-beta1, derived from neuroglia, were the most preva-
lent cytokines in brain tissues. Cerebrospinal fluid (CSF)
showed a unique proinflammatory profile of cytokines, in-
cluding a marked increase in MCP-1 [36].
Elevated levels of chemokines have been detected in
the brain and CSF of individuals with autism. Few stu-
dies have examined chemokine levels in the plasma of
children with autism, but these studies did not correlate
the plasma levels of chemokines with the disease sever-
ity. Elevated plasma MCP-1, RANTES and eotaxin in
some autistic children and their association with more
impaired behaviors may have etiological significance.
Chemokines and their receptors might provide unique
targets for future therapies in autism [38]. Another study
reported decreased plasma levels of chemokines involved
Figure 1 Serum levels of MDC in autistic patients and healthy
controls. MDC, macrophage-derived chemokine. Horizontal bars
indicate the median values.
Figure 2 Serum levels of TARC in autistic patients and healthy
controls. TARC, thymus and activation-regulated chemokine.
Horizontal bars indicate the median values. TARC, thymus and
activation-regulated chemokine.
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in hematopoiesis and the Th cell immune system in
the children with autism compared with unrelated sib-
lings without autism. The investigators of this study
recommended further studies to confirm immuno-
logical disturbances influencing hematopoiesis and
antibody production in the children with autism [39].
An increased risk for infantile autism with elevated
MCP-1 in amniotic fluid was recently reported. Ele-
vated levels of MCP-1 may play an indirect role in the
pathophysiology of autism [40].
This study is the first to investigate serum levels of
CCR4 ligands in relation to the degree of the severity of
autism, which was assessed by using CARS. In the
present work, children with severe autism had signifi-
cantly higher serum levels of MDC than patients with
mild to moderate autism (P <0.001 and P = 0.01, respect-
ively). There were significant positive correlations be-
tween the values of CARS and serum levels of both
MDC (P <0.001) and TARC (P <0.001) in autistic
children. This may indicate that the extent of the eleva-
tion of CCR4 ligands was closely linked to the degree of
the severity of autism. However, it is not easy to deter-
mine whether this increase is a mere consequence of
autism or has a pathogenic role in the disease. Further
research is warranted to determine the pathogenic role
of CCR4 ligands and their relation to serum levels of
brain-specific autoantibodies in autistic children.
CCR4 ligands have many cellular sources including
monocyte-derived dendritic cells, keratinocytes and
bronchial epithelial cells [41-43]. MDC is also produced
by natural killer cells and macrophages [44]. Early
signals elicited during innate immune response, such as
Th2-type cytokines and bacterial products, induce the
rapid secretion of CCR4 [45,46]. The current study revealed
significant positive correlations between serum MDC and
serum TARC levels in autistic children (P <0.001). This
could be explained by the fact that MDC is produced con-
comitantly with TARC during immune inflammation. Both
chemokines are ligands to the same receptor, which is char-
acterized on Th2 cells [9] resulting in the activation and
long-term recruitment of Th2 cells [47] and subsequently
in the pathomechanism of some autoimmune diseases, in-
cluding autism [15-17].
Both Th2 chemoattractants, MDC and TARC, were
reported to be elevated and play a role in some auto-
immune diseases such as systemic lupus erythematosus
Table 1 Serum levels of MDC and TARC in relation to the severity of autism
Serum CCR4
ligands
Patients with mild to moderate autism (n = 20) Patients with severe autism (n = 36) Z (P-value)
Median (IQR) Median (IQR)
Serum MDC (pg/ml) 767.5 (649) 634 (451) 4.8 (< 0.001)
Serum TARC (pg/ml) 1623 (651) 1469 (1217) 3.2 (0.01)















r = 0.903, p<0.001
Figure 3 Positive correlations between serum levels of MDC and TARC in autistic patients. MDC, macrophage-derived chemokine, TARC,
thymus and activation- regulated chemokine.
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[15] and systemic sclerosis [16]. In addition, MDC levels
were reported to be elevated in the CSF of female patients
with multiple sclerosis (MS). MDC was suggested to play
a role in the development of MS possibly by influencing
the intracerebral recruitment of Th2 cells which express
CCR4 receptors [17]. Furthermore, MDC plays a role in
experimental autoimmune encephalomyelitis (EAE), the
animal model of MS. MDC/CCL22 gene is a part of a che-
mokine cluster, which includes also TARC/CCL17. The
frequency of the C/T and C/A single nucleotide polymor-
phisms (SNPs) in the promoter and coding sequence of
CCL22 as well as the C/T SNP in the promoter of CCL17
were determined in 370 patients with MS compared with
380 controls. A trend toward a decreased allelic frequency
of the A allele of the CCL22 C/A SNP as well as of the T
allele of the CCL17 C/T SNP was found in patients com-
pared with controls [19]. Similar genetic studies of MDC/
CCL22 gene are recommended in children with autism.
The immunomodulatory effects of CCR 4 ligands may
act not only through modulation of Th cell function, but
also through decreasing the induction of CD4 + CD25high
regulatory T cells (T-regs) and the promotion of the differ-
entiation of Th17 cells [48]. Th17 cells have been impli-
cated in the pathogenesis of autoimmune diseases, which
is supported by recent clinical trials using anti-IL-17 in
the treatment of these diseases. Th17 cells are characte-
rized by a strong IL-17-producing capacity. IL-17 family
cytokines control the inflammatory responses by trig-
gering the secretion of proinflammatory cytokines and
chemokines [49,50]. In addition, T-regs play an important
role in the establishment of the immunological self-
tolerance and thereby, prevent autoimmunity as T-regs
suppress Th17 cells [51]. One study reported deficiency
of T-regs in 73.3% of autistic children [32]. Another
studies reported significantly higher plasma concentra-
tions of IL-17 [37,52] and some of Th2 cytokines,
such as IL-5 and IL-13, in autistic children compared
to healthy matched controls [37,38].
Previous studies reported the possible pathogenic role
of Th2 cells, Th17 cells and deficiency of T-regs in the
induction of autoimmunity in a subgroup of patients
with autism [32,35,36,50]. The results of this study may
indicate the possible contributing role of CCR4 ligands
in the induction of autoimmunity in autism, possibly as
a result of long-term recruitment of Th2 cells, suppres-
sion of the induction of T-regs and enhancement of the
differentiation of Th17 cells. However, this is an initial
report that cannot prove the pathogenic role of CCR4 li-
gands in autism, but rather raises additional questions.
So, these data should be treated with caution until fur-
ther investigations are performed. Studies should be
conducted to investigate the relationship between serum
levels of CCR4 ligands and both T-regs and Th17 cells
in children with autism.
Decreasing chemokine receptor binding may be an im-
portant potential therapeutic target in allergy and immu-
nology [4]. This can be performed by using small
molecule chemokine receptors antagonists or by using
blocking antibodies [53]. Thus, studies concerning the ef-
fect of CCR4-ligand antagonism on amelioration of autis-
tic manifestations in children are mandatory.
Conclusions
Serum levels of CCR4 ligands were elevated in autistic
children and they were significantly correlated to the de-
gree of the severity of autism. However, further research
is warranted to determine the pathogenic role of CCR4
ligands in autism and to shed light on the therapeutic
role of CCR4-ligand antagonism in autistic children.
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